Completed vaccination on 2019, had shingles in 2021/ suspected vaccination failure; Shingles in eye and cornea; Shingles affected face; This case was reported by a nurse via call center representative and described the occurrence of vaccination failure in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis, PNEUMOCOCCAL VACCINE POLYSACCHARIDE 23 VALENT (PNEUMOVAX 23) for prophylaxis and COVID-19 VACCINE for prophylaxis.   Previously administered products included Pneumovax 13 (received pneumovax 13 on 19 December 2018). Additional patient notes included the patient was not immunocompromised.   On 26th December 2019, the patient received the 2nd dose of Shingrix (intramuscular). On 16th October 2019, the patient received the 1st dose of Shingrix (intramuscular). On 26th December 2019, the patient received PNEUMOVAX 23. On an unknown date, the patient received COVID-19 VACCINE. On an unknown date, more than a year after receiving Shingrix and Shingrix and an unknown time after starting Valacyclovir, the patient experienced vaccination failure (serious criteria medically significant), ophthalmic herpes zoster (serious criteria medically significant) and shingles. The patient was treated with valaciclovir (Valacyclovir) and unknown steroid eyedrops (Steroid Eye Drops). On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the ophthalmic herpes zoster and shingles were recovered/resolved.   It was unknown if the reporter considered the vaccination failure, ophthalmic herpes zoster and shingles to be related to Shingrix and Shingrix.     Linked case(s) involving the same patient:  2022AMR143929   Additional Information: Receipt Date: 05-AUG-2022 Reporter's Comment: The reporter was patient who was nurse. The patient stated that had Shingrix shot 1 on 16th October 2019 and Shingrix Shot number 2 and also Pnumovax 23 on 26th December 2019.  The patient did not have the lot numbers. The patient developed shingles in 2021 this happened 10 days after having patient first Covid-19 shot. Patient states this was reported to the CDC VAERS.  It afftected the patient's face and went into her eyes and cornea. Since then had multiple re-occurrences where they thought it had cleared up but it popped back up again and it might had been the same infection which never fully resolved. The patient had been treated with valacyclovir. The patient last reoccurrence was in April 2022 and was mild but was in the eye. The patient was still on valacyclovir 500 mg daily as maintenance and a steroid eye drop every other day. She was told she might have to stay on these medications forever. In 2021, 10 Days after Covid vaccine the patient developed shingles and ophthalmic herpes zoster. In 2021 more than a year after receiving Pneumovax 23 vaccine , the patient experienced ophthalmic herpes zoster and shingles. It was unknown if the reporter considered the ophthalmic herpes zoster and shingles to be related to Pneumovax 23 and covid 19 vaccine. Additional supportive information: This case was considered as suspected vaccination failure as details regarding  laboratory confirmation were not known at the time of reporting. Reporter consented to follow up. This case is linked with 2022AMR143929 same reporter.; Sender's Comments:  2022AMR143929:same reporter, same patient